Predictive Model Of Response To Blinatumomab Therapy In Children And Adults With Relapsed/Refractory B-All

BLOOD(2020)

引用 1|浏览27
暂无评分
摘要
Background.Blinatumomab is a monoclonal BITe antibody recently introduced for the treatment of relapsed and refractory (r\r) B-ALL. Response rate reaches 65-85% in different subgroups of patients but currently there is no reliable methods to predict response. Using results of the analysis of the efficacy of blinatumomab therapy in heterogenic cohort r/r B-ALL patients, including adults and children, we built a mathematical model to predict response to this antibody.
更多
查看译文
关键词
Treatment Outcomes,Relapse Risk
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要